Crossmark

A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension

Crossref DOI link: https://doi.org/10.1038/s41440-024-01657-z

Published Online: 2024-04-17

Published Print: 2024-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Fang

Liu, Ling

Ruan, Hongyun

Chen, Xiaoping

Zhang, Yue

Yu, Zaixin

Li, Yuhui

Guan, Yang

Wang, Jiguang

Huang, Kai

Yu, Shunjiang

Cao, Yuanyuan

Ding, Cungang

Chang, Lin

Huang, Yaohua

Chen, Xiangjuan

Lv, Qiang

Ma, Changsheng
License Information

Text and Data Mining valid from 2024-04-17

Version of Record valid from 2024-04-17
More Information

Article History

Received: 7 November 2023

Revised: 29 January 2024

Accepted: 1 March 2024

First Online: 17 April 2024

Compliance with ethical standards

:

: SY, YC, CD, LC, YH and XC are employees of Shanghai Pharmaceuticals Holding Co., Ltd, China. All the other authors have no conflicts of interest regarding the content of this article.

Document is current

Any future updates will be listed below